Please login to the form below

Nippon Shinyaku

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Nippon Shinyaku's Japan sales performance.

Biosimilar Remicade reaches market in Japan and India

India. In Japan, Nippon Kayaku has launched a biosimilar version of Remicade (infliximab) originally developed by South Korean biotechnology company Celltrion, which was approved for marketing in July. ... Nippon Kayaku said infliximab is the second

Deal Watch table for September 2013

50. 5. Shin Nippon Biomedical / Transcept Pharma. Licence. TO-2070 nasal powder for acute migraine.

First biosimilar mAb gets the nod in EU

In Japan the drug will be co-marketed by Celltrion's development partner Nippon Kayaku. .

New formulations of Pralia and Enbrel head list of new drugs in Japan

line extension - which like its predecessor will be co-promoted by Nippon Boehringer Ingelheim - is expected to provide better control of high blood pressure over 24 hours.

An eye towards the biobetter in South Korea

Location. Status. Herceptin (trastuzumab). CT-P6. Celltrion. Hospira, Nippon Kayaku. Breast cancer. ... Remsima. Celltrion. Hospira, Nippon Kayaku. RA, AS, CD, PA, PS, &UC.

1 2 3 [ Next 5 results ]

Data provided by GlobalData

GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.

To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com

For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology

Featured jobs

Creative/ Medical Writer: Circa £35, 000 With Benefits

Managing Director – Global Medical Writing & Scientific Exce...: £120-150K

AM – Corporate Comms/ Public Affairs/ B2B – Healthcare Focus: Salary TBC

Home-based Medical Writer – Medical Education: Salary TBC

Home-based Senior Medical Writer – Med Ed: Salary TBC

Senior Account Executive – Account Manager – Healthcare Advertis...: £32000 - £43000 Bonus Benfits

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Account Director, Healthcare Marketing Agency: Salary TBC

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Senior Medical Writer: Salary TBC

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Senior Digital Health Specialist – Global Agency: Salary TBC

EU Head of Business Development and Client Service: Exceptional packge and bonus

Account Director, Medical Education: Salary TBC

Scientific Director – Medical Communications: Salary TBC

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Senior Account Director – Healthcare Advertising – London: Salary TBC

Health Consultant - Brand Comms: Competitive Salary

Home based, Senior Medical Writer, Medical Communications: Excellent package

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Senior Account Manager, Medical Communications, London: Excellent package

Programme/ Account Director - Healthcare PR - London: Salary TBC

Associate Director – Social Healthcare – London: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Account Manager, MedicalCommunications/ Healthcare PR: benefits

50 questions for delivering an exceptional healthcare brand experience: Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution: Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence: Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....